Mpox study in Africa to continue with support from Emergent and PANTHER.

Emergent BioSolutions and PANTHER have agreed to provide additional funding to continue the Africa CDC-led Mpox Study in Africa (MOSA), and an independent monitoring board reported no safety concerns after reviewing the first 50 randomized patients.

Emergent BioSolutions and PANTHER announced an agreement to provide additional financial support for the Africa CDC-led Mpox Study in Africa (MOSA). MOSA is a double-blind, platform-adaptive clinical trial launched in 2024 to evaluate potential treatments for mpox. An independent data and safety monitoring board completed an initial safety review in December 2025 after 50 patients were randomized and recommended that the trial continue. The trial initially received funding from the European Union and Africa CDC. Key facts: - The announcement was made on Jan. 8, 2026, and describes additional funding to sustain MOSA operations. - MOSA is designed to evaluate treatment options for patients with mpox across multiple African countries using a platform-adaptive design. - The DSMB reviewed safety data after the first 50 patients were randomized and reported no safety concerns, recommending continuation of the trial. - Africa CDC and PANTHER plan to extend MOSA to additional sites, including a site in Uganda, and to enroll patients to reach the next milestone. - Africa CDC reports that since early 2024 the continent has recorded more than 61,383 confirmed mpox cases and 296 deaths across 32 countries, and that both major mpox clades (Clade I and Clade II) are present in Africa. Summary: The added support from Emergent and PANTHER is intended to keep MOSA running while investigators gather more clinical evidence on mpox treatments. With the DSMB's initial safety recommendation, organizers plan to open additional sites and enroll more participants to reach the next trial milestone; specific timelines were not provided.